Condition: Degenerative Osteoarthritis · Sponsor: Kolon TissueGene, Inc.
A randomized, double-blind, placebo-controlled, multi-center, phase 3 study to determine the efficacy and safety of TG-C in subjects with Kellgren and Lawrence Grade 2 or 3 Osteoarthritis of the Knee, Osteoarthritis Research Society International (OARSI) medial joint space narrowing (JSN) Grade 1 or 2 of the knee joint. TG-C is to be administered by a single intra-articular injection to the damaged joint area via ultrasound guidance. Patients will be followed for 24 months for safety and efficacy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Nebojsa Skrepnik | Tucson, Arizona, United States | — |
| Steve Sitar | Anaheim, California, United States | — |
| Stuart Silverman | Beverly Hills, California, United States | — |
| Samy Metyas | Covina, California, United States | — |
| Bassil Aish | Huntington Beach, California, United States | — |
| Peter Hanson | La Mesa, California, United States | — |
| Duane Anderson | San Diego, California, United States | — |
| Miguel Trevino | Clearwater, Florida, United States | — |
| Jan Hommen | Doral, Florida, United States | — |
| Mira Baron | West Palm Beach, Florida, United States | — |
| Richard Radnovich | Boise, Idaho, United States | — |
| Thomas Schnitzer | Chicago, Illinois, United States | — |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03291470